CDKN2A/B纯合性缺失与脑膜瘤的早期复发相关。 - Suppr

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.

作者信息

Sievers Philipp, Hielscher Thomas, Schrimpf Daniel, Stichel Damian, Reuss David E, Berghoff Anna S, Neidert Marian C, Wirsching Hans-Georg, Mawrin Christian, Ketter Ralf, Paulus Werner, Reifenberger Guido, Lamszus Katrin, Westphal Manfred, Etminan Nima, Ratliff Miriam, Herold-Mende Christel, Pfister Stefan M, Jones David T W, Weller Michael, Harter Patrick N, Wick Wolfgang, Preusser Matthias, von Deimling Andreas, Sahm Felix

机构信息

Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Clinical Cooperation Unit Neuropathology (B300), German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

出版信息

Acta Neuropathol. 2020 Sep;140(3):409-413. doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.

DOI:10.1007/s00401-020-02188-w

PMID:32642869

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7423850/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69fd/7423850/5d5fc90f9c4f/401_2020_2188_Fig1_HTML.jpg

相似文献

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.

Acta Neuropathol. 2020 Sep;140(3):409-413. doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.

Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.

Acta Neuropathol. 2023 Apr;145(4):497-500. doi: 10.1007/s00401-023-02544-6. Epub 2023 Feb 1.

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.

Acta Neuropathol. 2023 Jul;146(1):145-162. doi: 10.1007/s00401-023-02571-3. Epub 2023 Apr 24.

p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.

Am J Surg Pathol. 2024 Jan 1;48(1):46-53. doi: 10.1097/PAS.0000000000002148. Epub 2023 Nov 10.

[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].

Zhonghua Bing Li Xue Za Zhi. 2024 May 8;53(5):439-445. doi: 10.3760/cma.j.cn112151-20230815-00069.

Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Am J Pathol. 2001 Aug;159(2):661-9. doi: 10.1016/S0002-9440(10)61737-3.

Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.

J Neuropathol Exp Neurol. 2022 Jan 29;81(2):117-126. doi: 10.1093/jnen/nlab127.

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

J Neurooncol. 2019 Dec;145(3):449-459. doi: 10.1007/s11060-019-03333-6. Epub 2019 Nov 15.

Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.

Acta Neuropathol. 2023 Apr;145(4):501-503. doi: 10.1007/s00401-023-02543-7. Epub 2023 Feb 2.

CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.

Acta Neuropathol Commun. 2023 Nov 28;11(1):189. doi: 10.1186/s40478-023-01690-y.

引用本文的文献

Spatially Encoded Oncogenesis and Transcriptional Plasticity in Meningioma: Drivers of Therapeutic Resistance and Opportunities for Targeted Intervention.

Cancers (Basel). 2025 Aug 19;17(16):2694. doi: 10.3390/cancers17162694.

Targeting epigenetic modifications as an emerging immunotherapeutic strategy for cancers.

Immunol Res. 2025 Aug 19;73(1):121. doi: 10.1007/s12026-025-09678-7.

The concept, intention, and evaluation of the term treatment-refractory meningioma.

J Neurooncol. 2025 Nov;175(2):599-610. doi: 10.1007/s11060-025-05154-2. Epub 2025 Aug 4.

EZH2 overexpression is associated with aggressive behavior and promotes cell proliferation in CNS WHO grade 3 meningiomas.

Neurooncol Adv. 2025 Jun 5;7(1):vdaf112. doi: 10.1093/noajnl/vdaf112. eCollection 2025 Jan-Dec.

Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification.

Nat Commun. 2025 Jul 2;16(1):6024. doi: 10.1038/s41467-025-61063-y.

Case Report: The price of intraoperative cell salvage? - implantation metastases of meningioma in both lungs and left cubital fossa.

Front Oncol. 2025 May 28;15:1535048. doi: 10.3389/fonc.2025.1535048. eCollection 2025.

Radiation-Induced Meningiomas Have an Aggressive Clinical Course: Genetic Signature Is Limited to Alterations, and Epigenetic Signature Is H3K27me3 Loss.

J Korean Med Sci. 2025 May 12;40(18):e62. doi: 10.3346/jkms.2025.40.e62.

Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival.

J Neurooncol. 2025 May 12. doi: 10.1007/s11060-025-05057-2.

Comprehensive analysis of prognosis and tumor immune microenvironment of cuproptosis-related gene CDKN2A in lung adenocarcinoma.

BMC Pulm Med. 2025 Apr 14;25(1):179. doi: 10.1186/s12890-025-03631-y.

Meningioma: Novel Diagnostic and Therapeutic Approaches.

Biomedicines. 2025 Mar 7;13(3):659. doi: 10.3390/biomedicines13030659.

本文引用的文献

Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.

J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):378-387. doi: 10.1136/jnnp-2019-322257. Epub 2020 Feb 10.

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

J Neurooncol. 2019 Dec;145(3):449-459. doi: 10.1007/s11060-019-03333-6. Epub 2019 Nov 15.

DNA methylation-based classification of central nervous system tumours.

Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Lancet Oncol. 2017 May;18(5):682-694. doi: 10.1016/S1470-2045(17)30155-9. Epub 2017 Mar 15.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.

Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.

Acta Neuropathol. 2016 Jun;131(6):903-10. doi: 10.1007/s00401-015-1519-8. Epub 2015 Dec 15.

TERT Promoter Mutations and Risk of Recurrence in Meningioma.

J Natl Cancer Inst. 2015 Dec 13;108(5). doi: 10.1093/jnci/djv377. Print 2016 May.

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Acta Neuropathol. 2013 Dec;126(6):907-15. doi: 10.1007/s00401-013-1195-5. Epub 2013 Oct 24.

Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.

Clin Cancer Res. 2010 Aug 15;16(16):4155-64. doi: 10.1158/1078-0432.CCR-10-0891. Epub 2010 Aug 3.

New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology.

J Clin Oncol. 2003 Sep 1;21(17):3285-95. doi: 10.1200/JCO.2003.07.156.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献